Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 8:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 3,910 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypertension Clear all
Completed Phase 4 Interventional Results available

Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)

NCT02191137
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Riociguat (Adempas, BAY63-2521)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
58
States / cities
Tucson, Arizona • La Jolla, California • Moreno Valley, California + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 28, 2026, 8:38 PM EDT
Completed No phase listed Observational

Prediction of 30-Day Readmission Using Machine Learning

NCT04849312
View directory record Official record
Conditions
Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 28, 2026, 8:38 PM EDT
Completed Not applicable Interventional

Personalized Physician Learning to Improve Hypertension Care

NCT00903071
View directory record Official record
Conditions
Hypertension
Interventions
Real PPL, Sim PPL
Behavioral
Lead sponsor
HealthPartners Institute
Other
Eligibility
22 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Oct 28, 2026, 8:38 PM EDT
Terminated Not applicable Interventional Results available

Optic Nerve Head Structural Response to IOP Elevation in Patients With Keratoconus

NCT03560609
View directory record Official record
Conditions
Keratoconus, Glaucoma
Interventions
Ophthalmodynamometer, Goldmann applanation tonometer, Pentacam, ORA, Optical Coherence Tomography (OCT)
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 28, 2026, 8:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Aerobic Exercise with Blood Flow Restriction on Post-exercise Hypotension in Young Adults: the Role of Histamine Receptors

NCT06629337
View directory record Official record
Conditions
Prehypertension (elevated Blood Pressure) or Hypertension
Interventions
H1 receptor blockade: 540 mg (Allegra), H2 receptor blockade: 40 mg (Pepcid AC)
Genetic
Lead sponsor
California Baptist University
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 28, 2026, 8:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of a Lifestyle Medicine Practice

NCT03739034
View directory record Official record
Conditions
Chronic Lifestyle Related Disease, Diabetes, Overweight and Obesity, Dyslipidemias, Hypertension, Cardiovascular Diseases
Interventions
Lifestyle Medicine
Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 28, 2026, 8:38 PM EDT
Not yet recruiting Not applicable Interventional

Tailoring TM-HTN Intervention for Black Patients

NCT06593119
View directory record Official record
Conditions
Hypertension
Interventions
Telemedicine management of Hypertension, Usual Care
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 28, 2026, 8:38 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Acupuncture Treatment on Cerebral Blood Flow

NCT04346511
View directory record Official record
Conditions
High Blood Pressure
Interventions
Acupuncture
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Norman, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 28, 2026, 8:38 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

NCT03689244
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension
Interventions
Selexipag, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 85 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
32
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 28, 2026, 8:38 PM EDT
Completed Phase 2 Interventional

Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension

NCT00046319
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
BSF 208075
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2009 · Synced Oct 28, 2026, 8:38 PM EDT
Completed Phase 1 Interventional

Pilot Study of the Safety and Efficacy of Anakinra in Pulmonary Arterial Hypertension

NCT03057028
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Anakinra
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 28, 2026, 8:38 PM EDT
Completed Not applicable Interventional

Hispanic Secondary Stroke Prevention Initiative

NCT02251834
View directory record Official record
Conditions
Stroke
Interventions
Community Health Worker (CHW), usual care and health education brochures every 4 months.
Behavioral · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 28, 2026, 8:38 PM EDT
Completed Not applicable Interventional Results available

Oral Nifedipine Versus Oral Labetalol

NCT02168309
View directory record Official record
Conditions
Severe Postpartum Hypertension
Interventions
Labetalol, Nifedipine
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 28, 2026, 8:38 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Allopurinol for Renal Transplant Associated Hypertension in Children

NCT00288171
View directory record Official record
Conditions
Hypertension, Renal Transplant
Interventions
Placebo, Allopurinol
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 28, 2026, 8:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

BVA-200 vs BVA-100 Validation Study

NCT06227819
View directory record Official record
Conditions
Heart Failure, High Blood Pressure, High Cholesterol, Anemia, Diabetes, Thyroid Diseases, Kidney Diseases, Clotting Disorder, Trauma, Other Disease
Interventions
BVA-200
Diagnostic Test
Lead sponsor
Daxor Corporation
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Oak Ridge, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Oct 28, 2026, 8:38 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome

NCT04327934
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Hypertension
Interventions
GnRH antagonist, GnRH antagonist + MethylTESTOSTERone 5 MG
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 28, 2026, 8:38 PM EDT
Completed Phase 3 Interventional

Study of Co-administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe Hypertension

NCT00185133
View directory record Official record
Conditions
Hypertension
Interventions
Olmesartan medoxomil, Amlodipine
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
139
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2018 · Synced Oct 28, 2026, 8:38 PM EDT
Completed No phase listed Observational

Using SCOUT Noninvasive AGE Measurements to Forecast Diabetes Complications

NCT01415115
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Not listed
Lead sponsor
VeraLight, Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Hyattsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2011 · Synced Oct 28, 2026, 8:38 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Labetalol Versus Magnesium Sulfate (MgSO4) for the Prevention of Eclampsia Trial

NCT00293735
View directory record Official record
Conditions
Preeclampsia, Pregnancy Induced Hypertension, Gestational Hypertension, Chronic Hypertension, Superimposed Preeclampsia
Interventions
labetalol (seizure prevention), MgSO4 (seizure prevention)
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
15 Years to 60 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 28, 2026, 8:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Role of Endothelin in Pulmonary Hypertension

NCT00759408
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
BQ-123
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 28, 2026, 8:38 PM EDT
Not listed No phase listed Observational

Endothelial Biomarkers of Systemic Sclerosis-associated Pulmonary Hypertension

NCT03459716
View directory record Official record
Conditions
Scleroderma, Pulmonary Hypertension
Interventions
No intervention
Other
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
56 participants
Timeline
2018 – 2021
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 10, 2021 · Synced Oct 28, 2026, 8:38 PM EDT
Recruiting Not applicable Interventional

SPYRAL GEMINI Pilot Study

NCT06907147
View directory record Official record
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Interventions
Multi-Organ Denervation Gemini System
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years to 80 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Stanford, California • Orlando, Florida • Safety Harbor, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 8:38 PM EDT
Completed Not applicable Interventional

When the Kidney Reacts to Nutritional Changes

NCT04142138
View directory record Official record
Conditions
Prehypertension
Interventions
DASH
Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 28, 2026, 8:38 PM EDT
Recruiting No phase listed Observational

Pulmonary Hypertension (PH) Biorepository for Translational Research

NCT07647549
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
3
States / cities
Baltimore, Maryland • Bethesda, Maryland • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 28, 2026, 8:38 PM EDT